CBA Share Price Today: Commonwealth Bank of Australia Stock (ASX:CBA) in Focus on 18 December 2025 as Options Expiry, Rate Outlook and Analyst Targets Collide

CBA Share Price Today: Commonwealth Bank of Australia Stock (ASX:CBA) in Focus on 18 December 2025 as Options Expiry, Rate Outlook and Analyst Targets Collide

Commonwealth Bank of Australia (ASX: CBA) shares are back in the spotlight on Thursday, 18 December 2025 — not because the bank dropped a blockbuster announcement, but because the market is juggling three forces at once: year-end options expiry volatility, a shifting interest-rate outlook for 2026, and a persistent debate about whether CommBank’s valuation still makes sense at today’s price.

As of 18 December, CBA was trading around A$154.56, up modestly on the day, after moving between A$153.11 and A$154.67. Investing.com’s snapshot put CBA’s market capitalisation at roughly A$258 billion and showed a 52‑week range of A$140.21 to A$192.00 — a reminder that the share price is still well below its mid‑year highs even after years of outperformance. [1]

Why CBA shares are jumpy today: options expiry distortions are real (and temporary)

One very practical reason CBA is getting extra attention on 18 December is mechanical rather than fundamental: it’s options expiry day.

MarketIndex flagged that pre‑market pricing was unusually volatile, citing CBA as an example and noting an indicative open down about 5% at one point — the kind of move that can appear dramatic before the opening auction clears expiry-related imbalances and hedging pressure eases. In plain English: on days like this, prices can look “weird” early and then normalise once the market properly opens. [2]

This matters for investors reading headlines: expiry-day swings don’t automatically mean “new information” about the bank. Sometimes it’s just the plumbing.

The bigger macro driver: markets are repricing the 2026 rate path

The macro story that keeps looping back into Australian bank stocks — including CBA — is interest rates.

Earlier this week, a Reuters market report carried by TradingView said economists at Commonwealth Bank of Australia and National Australia Bank were expecting the Reserve Bank of Australia to start raising rates as early as February 2026, after the RBA’s final 2025 meeting signalled a more hawkish tilt while inflation pressures lingered. The same report pointed to rising market-implied odds of a hike (via rate-swap pricing). [3]

Separate reporting in The Australian (published 16 December) added colour on what the banks’ economists were projecting: CBA forecasting a 25bp hike to 3.85%, while NAB expected two hikes (50bp total) in the first half of 2026 — though other major-bank forecasters were not aligned. [4]

Why does this matter for CBA shareholders?

  • Higher rates can support bank margins (what banks earn on loans versus what they pay for funding), but…
  • Higher rates can also slow credit growth and, at the extreme, worsen arrears and loan losses if household stress rises.
  • And in a competitive mortgage market, banks can end up competing away some of the benefit anyway.

CBA is especially sensitive to mortgage dynamics because it is a heavyweight in Australian home lending — and because its share price is often treated as a “quality compounder” proxy in local portfolios.

The central tension: CBA is cheaper than its peak — but many analysts still see downside

Even after falling from its 2025 high, CBA remains the bank most likely to trigger the same question at barbecues and investment committees alike: “Is it still overpriced?”

On 18 December, Investing.com’s analyst consensus data painted a stark picture:

  • Average 12‑month price target: ~A$121.36
  • High estimate:A$146
  • Low estimate:A$96.07
  • Analyst stance shown:0 buy / 14 sell (overall “Strong Sell”) [5]

Those figures imply a meaningful gap between where the stock trades today and where the “average” analyst target sits — essentially the market saying, “we’ll pay up for CBA,” while the analyst community says, “we’re not paying that much.”

What are the bears focusing on?

The bearish case usually comes down to some combination of:

  1. Valuation premium vs peers
  2. Limited growth in a mature banking market
  3. Competition (especially in mortgages and deposits)
  4. Any sign margins are rolling over or costs are creeping up

A September UBS note carried by Investing.com reiterated a Sell rating with a A$125 target, explicitly framing CBA as overvalued in UBS’s view. [6]

And in October, Reuters reported that even as CBA extended CEO Matt Comyn’s tenure, the bank was being described as one of the most expensive banks globally, citing a price‑to‑earnings ratio of 27.2x and a forward price‑to‑book ratio of 3.37x at the time — well above domestic rivals and many global banks. [7]

Why valuation keeps coming up: the “great bank, pricey stock” problem

To understand why CBA’s valuation is a recurring headline, it helps to separate business quality from share price expectations.

CBA has posted strong profitability and has historically been rewarded for its scale, brand, funding profile, and execution. In August, Reuters reported CBA delivered record full‑year cash earnings of A$10.25 billion and a record dividend payout of A$4.85 per share, with net interest margin rising to 2.08%. [8]

But that same Reuters report also captured the pushback: investors “dumped” the stock on the day despite the record result, and fund managers argued the premium looked disconnected from growth and returns — essentially warning that when you pay “luxury pricing,” you need “luxury surprises” to keep the share price moving higher. [9]

That dynamic still hangs over CBA on 18 December:

  • If results are merely “fine,” the premium can compress.
  • If results exceed expectations, CBA’s valuation can look justified (or at least survivable).
  • If margins disappoint, the stock can react sharply because there’s less valuation “cushion.”

Near-term calendar: the next big CBA catalyst is February 2026

For investors looking beyond today’s expiry-driven noise, the next major checkpoint is already on CBA’s official calendar.

Commonwealth Bank’s investor timetable lists:

  • Half-year results and interim dividend announcement:11 February 2026
  • Ex-dividend date (interim):18 February 2026
  • Record date:19 February 2026
  • Interim dividend payment date:30 March 2026 (on or around) [10]

This matters because, for many Australian investors, CBA is owned as much for income and franking as for capital growth. Dividend expectations can stabilize sentiment — or amplify disappointment — depending on what the bank signals about payout sustainability, growth, and costs.

Regulatory and cross-border headlines investors are factoring in this week

Not all “CBA stock news” is about earnings. Two recent policy/regulatory developments remain relevant going into year-end positioning.

1) Consumer Data Right penalty (Australia)

Reuters reported in early December that CBA paid a penalty of A$792,000 after the ACCC issued infringement notices alleging breaches of Consumer Data Right (CDR) rules related to data sharing for some business and partnership accounts. CBA said it identified and voluntarily reported the issue and accepted the investigation’s findings. [11]

For long-term valuation, this isn’t likely a “make-or-break” dollar amount. But investors do pay attention to anything that hints at operational or compliance friction — especially when a stock trades at a premium.

2) New Zealand bank capital rules (affecting ASB, part of CBA)

CBA also has material exposure to New Zealand through ASB Bank, and that channel got a notable headline this week.

Reuters reported the Reserve Bank of New Zealand will lower some capital requirements for the big Australian-owned banks operating in NZ after reviewing rules introduced in 2019. The report said the top four Australian-owned banks would face a common equity tier 1 requirement of 12% (down from 16%), while other components (including tier 2 and internal loss-absorbing capacity) would change. The RBNZ estimated the changes would reduce funding costs and deliver net benefits versus the prior framework. [12]

For CBA investors, the practical question isn’t “Is this good or bad?” in isolation — it’s how much it changes competitive intensity, pricing, and returns in NZ, and whether any benefit is competed away.

What investors are really deciding on 18 December 2025

If you strip away the expiry-day mechanics and the daily tape, CBA shareholders (and would-be shareholders) are effectively choosing between two narratives:

Narrative A: “CBA is the quality bank; the premium is earned”

This view argues:

  • CBA’s franchise strength and scale justify a higher multiple.
  • Dividend reliability and franking are valuable, especially in volatile markets.
  • Even modest growth is acceptable if risk is low and execution is strong.

Narrative B: “A premium can become a trap when growth normalises”

This view argues:

  • The stock is priced for near-perfection.
  • Competition (mortgages, deposits, business banking) limits upside.
  • Any macro wobble (rates, housing, arrears) hits a premium multiple harder.

Recent Reuters reporting has captured both sides of this tension: record profitability and dividends on one hand, and persistent investor concern about the valuation multiple on the other. [13]

Bottom line for CBA stock today

On 18 December 2025, Commonwealth Bank of Australia shares are being pulled by short-term trading mechanics (options expiry), macro repricing (the 2026 rate outlook), and a long-running valuation argument that still hasn’t been settled.

The stock is well off its 2025 highs, yet consensus-style analyst data still points to targets materially below the current share price — a signal that the market’s willingness to pay a premium for CBA remains the key variable. [14]

The next clean “fundamental verdict” is likely to arrive with CBA’s half-year results on 11 February 2026 — when management commentary on margins, competition, credit quality and dividends will either reinforce the premium… or invite the market to haggle harder. [15]

References

1. uk.investing.com, 2. www.marketindex.com.au, 3. www.tradingview.com, 4. www.theaustralian.com.au, 5. uk.investing.com, 6. www.investing.com, 7. www.reuters.com, 8. www.reuters.com, 9. www.reuters.com, 10. www.commbank.com.au, 11. www.reuters.com, 12. www.reuters.com, 13. www.reuters.com, 14. uk.investing.com, 15. www.commbank.com.au

Stock Market Today

  • ImmunityBio (IBRX) Emerges as a Top NASDAQ Stock Under $10, Backed by Major Upgrades
    December 18, 2025, 5:56 AM EST. ImmunityBio, Inc. (IBRX) remains a focal point among NASDAQ stocks under $10. On Dec. 15, Piper Sandler reiterated a Buy with a $5 target, implying about 125% upside from current levels. Three days earlier, Jefferies raised its target to $9 from $8 and reiterated a Buy, signaling more than 250% upside as the EMA moves toward conditional marketing authorization for Anktiva in NMIBC-CIS. Jefferies also notes ongoing geographic and commercial expansion and advancing its pipeline, with regulatory dialogue on papillary disease and a forthcoming NCCN guideline decision that could unlock another label expansion for BCG-naïve data. Across all five analysts, the stock shows a consensus Buy, with targets spanning $5-$24 and a median of $8, suggesting about 260% upside. ImmunityBio, founded in 2014, aims to harness the immune system against cancer and infectious disease.
Australia Stock Market Today (18 December 2025): ASX 200 slips as tech and uranium sink, Austal lands $1.03bn defence contract
Previous Story

Australia Stock Market Today (18 December 2025): ASX 200 slips as tech and uranium sink, Austal lands $1.03bn defence contract

Westpac (ASX: WBC) Share Price Today: Dividend Payment Nears as Westpac Shifts Its RBA Forecast to a 2026 Hold
Next Story

Westpac (ASX: WBC) Share Price Today: Dividend Payment Nears as Westpac Shifts Its RBA Forecast to a 2026 Hold

Go toTop